CD63 and invasive breast carcinoma: Instead, the levels of total CD63, as measured with our experimental CD63 IA, were significantly different between the control and case groups and there was a clear indication that the CD63 IA could have some diagnostic ability for early stage BrCa according to ROC analysis (AUC = 0.835).